MARIA ICIAR
ASTIGARRAGA AGUIRRE
PROFESORADO ASOCIADO
University Medical Center Hamburg-Eppendorf
Hamburgo, AlemaniaPublicaciones en colaboración con investigadoras/es de University Medical Center Hamburg-Eppendorf (12)
2024
-
ATM germ line pathogenic variants affect outcomes in children with ataxia-telangiectasia and hematological malignancies
Blood, Vol. 144, Núm. 11, pp. 1193-1205
2020
-
Neuroinflammatory Disease as an Isolated Manifestation of Hemophagocytic Lymphohistiocytosis
Journal of Clinical Immunology, Vol. 40, Núm. 6, pp. 901-916
-
Stem cell transplantation for children with hemophagocytic lymphohistiocytosis: Results from the HLH-2004 study
Blood Advances, Vol. 4, Núm. 15, pp. 3754-3766
2019
-
A multicenter study of patients with multisystem Langerhans cell histiocytosis who develop secondary hemophagocytic lymphohistiocytosis
Cancer, Vol. 125, Núm. 6, pp. 963-971
2018
-
Recommendations for the Use of Etoposide-Based Therapy and Bone Marrow Transplantation for the Treatment of HLH: Consensus Statements by the HLH Steering Committee of the Histiocyte Society
Journal of Allergy and Clinical Immunology: In Practice, Vol. 6, Núm. 5, pp. 1508-1517
-
Treatment dilemmas in asymptomatic children with primary hemophagocytic lymphohistiocytosis
Blood, Vol. 132, Núm. 19, pp. 2088-2096
2017
-
Confirmed efficacy of etoposide and dexamethasone in HLH treatment: Long-Term results of the cooperative HLH-2004 study
Blood, Vol. 130, Núm. 25, pp. 2728-2738
-
Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome
Journal of Pediatrics, Vol. 189, pp. 72-78.e3
2016
2015
-
Lack of bone lesions at diagnosis is associated with inferior outcome in multisystem langerhans cell histiocytosis of childhood
British Journal of Haematology, Vol. 169, Núm. 2, pp. 241-248
2013
-
Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years
Pediatric Blood and Cancer, Vol. 60, Núm. 2, pp. 175-184
-
Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis
Blood, Vol. 121, Núm. 25, pp. 5006-5014